Our specialist therapy areas – new

Gastroenterology

We have a long standing expertise in gastroenterology – from macrogol-based laxatives to bowel preparation.
We are looking to bring innovative products to markets to improve adenoma detection rate (ADR*) through improved visualisation techniques and products including devices such as ENDOCUFF VISION^®.

*ADR is the percentage of patients aged ≥50 years undergoing first-time screening colonoscopy who have one or more conventional adenomas detected and removed.

Hepatology

We are committed to the early detection and management of hepatic encephalopathy, a common and serious neuropsychiatric syndrome associated with cirrhosis.
In Europe 200,000¹ people are affected by hepatic encephalopathy yet it remains under-diagnosed and under-treated, as many patients and carers are unaware of the signs and symptoms of the disease. This results in poor quality of life for patients and a high burden on those who care for them.
Healthcare providers don’t always identify and treat the often subtle symptoms of hepatic encephalopathy which leads to mediocre patient outcomes and an increase in hospital admissions.

Galaxy Consortium

As part of our commitment to improve the management of hepatic encephalopathy we are a member of the Galaxy Consortium.
GALAXY has the ambition, by combining unique capabilities in European institutions, to perform integrated systems modelling of multi-omics data together with clinical data. GALAXY will investigate the precursor of alcoholic liver cirrhosis to enable early detection and treatment. This will ultimately result in a reduction of mortality, morbidity, healthcare costs and lost productivity.
The GALAXY project is funded by the European Union’s Horizon 2020 Framework Programme (Grant number 668031).

¹Amodio P, Del Piccolo F, Pettenò E, et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol. 2001;35(1):37-45.

Cancer and Supportive Care

We are committed to improve the diagnosis of patients with head and neck cancer, the seventh most common type of cancer in Europe, with more than 150,000 new patients diagnosed in Europe in 2012.¹
There are an estimated 400,000 to 600,000 new cases of all types of head and neck cancer globally each year and the mortality rate is between 223,000 and 300,000 deaths per year.²
We are also committed to ensuring early recognition of malignant hyperthermia an inherited, rare, life-threatening condition. Malignant hyperthermia is a rapid rise in body temperature which causes muscle stiffness and spasms and can occur during surgery with certain types of anesthesia.

¹http://makesensecampaign.eu/en/cancer-information/head- neck-cancer/ accessed on 14th March 2017
²http://www.who.int/selection_medicines/committees/expert/20/applications/HeadNeck.pdf accessed on 14th March 2017

COOKIES FRÅN FÖRSTA OCH TREDJE PART	NAMN	LEVERANTÖR	SYFTE	RETENTION
Tredje part	_ga_	google.com	Registrera besökarnas val av cookies.	400 dagar
Tredje part	_gat_gtag_	google.com	Registrerar spårningskoddata.	1 minut
Tredje part	_ga	google.com	Beräknar besökar-, sessions- och kampanjdata och håller även reda på hur webbplatsen används.	400 dagar
Tredje part	_gid	google.com	Registrerar ett unikt ID som används för att generera statistiska uppgifter om hur besökaren använder webbplatsen.	1 dag